Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Spartex who wrote (261)	2/2/1999 4:49:00 PM
From: Mike McFarland	Respond to of 3557

The breakout...neuropathy Geeze, what the heck? No PR, no news that I have found and the dang thing breaks out so fast no chance to hop on finally. This one has been on my list for the last year, but it was stuck in a trading range of $6-$8, or something like that for the last six months. So what is up--anybody slog through the yahoo board yet? Regeneron appears four times on this list...if anybody thinks they have a good feel for the best diabetic neuropathy dart, please share...I've got a couple of micros on the list, but they are not going anywhere fast so far. recap.com As of post 149 there was no news posten on yahoo board, some speculation about option call purchases, one reference to P&G, and a reference to Axokine, but no news yet. --Mike

To: Spartex who wrote (261)	2/2/1999 10:09:00 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 3557

QK: <<What is your rationale for favoring REGN to discontinue NT3 development "forever"? Being a diabetic, and still healthy, I'd love to see some progress on a drug that minimizes/reverses the onset of neuropathy, wouldn't you?>> I is not may rationale, it is REGN management perspective, and I agree. NT3 has side effects at higher doses, so to have needed therapeutic effects significant toxicity were observed. Also, other companies (pharma and bts) are looking seriously on this indication and they have advantage (small molecules). It is not tragic situation. NT3 may work in other indications. Constipation (niche market) seams as promising indication (BDNF and NT3). Miljenko